Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 445 participants.
Also called NCT07539259
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 445 participants
- Sponsor
- Registry
-
NCT07539259
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07539259. Randomized; no masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis
- Acronym
- RELIEF-AS
- Condition
- Aortic Stenosis
- Intervention (Drug)
- Dapagliflozin (DAPA)
- Intervention (Drug)
- Spironolactone (drug)
- Intervention (Drug)
- Spironolactone + Dapagliflozin
- Intervention (Drug)
- Epleronone
- Lead sponsor
- University College, London
Record details
- Record id
cardio:ct-nct07539259- Content hash
637e3494fbca3c8a865c21dd0a6e88dec09c24195aa405e1d0be30cadb110a01